Literature DB >> 34064028

Prevalence of Anti-SARS-CoV-2 Antibodies in Poznań, Poland, after the First Wave of the COVID-19 Pandemic.

Dagny Lorent1, Rafal Nowak1, Carolina Roxo1, Elzbieta Lenartowicz1, Aleksandra Makarewicz1, Bartosz Zaremba1, Szymon Nowak2, Lukasz Kuszel3, Jerzy Stefaniak2, Ryszard Kierzek1, Pawel Zmora1.   

Abstract

In comparison to other European countries, during the first months of the COVID-19 pandemic, Poland reported a relatively low number of confirmed cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. To estimate the scale of the pandemic in Poland, a serosurvey of antibodies against SARS-CoV-2 was performed after the first wave of COVID-19 in Europe (March-May 2020). Within this study, we collected samples from 28 July to 24 September 2020 and, based on the ELISA results, we found that 1.67% (25/1500, 95% CI 1.13-2.45) of the Poznan (Poland) metropolitan area's population had antibodies against SARS-CoV-2 after the first wave of COVID-19. However, the presence of anti-SARS-CoV-2 IgG antibodies was confirmed with immunoblotting in 56% (14/25) samples, which finally resulted in a decrease in seroprevalence, i.e., 0.93% (14/1500, 95% CI 0.56-1.56). The positive anti-SARS-CoV-2 IgG results were associated with age, occupation involving constant contact with people, travelling abroad, non-compliance with epidemiological recommendations and direct contact with the novel coronavirus. Our findings confirm the low SARS-CoV-2 incidence in Poland and imply that the population had little herd immunity heading into the second and third wave of the pandemic, and therefore, that herd immunity contributed little to preventing the high numbers of SARS-CoV-2 infections and COVID-19-related deaths in Poland during these subsequent waves.

Entities:  

Keywords:  COVID-19; Poland; SARS-CoV-2; antibodies; pandemic; seroprevalence

Year:  2021        PMID: 34064028     DOI: 10.3390/vaccines9060541

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  22 in total

1.  Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis.

Authors:  Adam Booth; Angus Bruno Reed; Sonia Ponzo; Arrash Yassaee; Mert Aral; David Plans; Alain Labrique; Diwakar Mohan
Journal:  PLoS One       Date:  2021-03-04       Impact factor: 3.240

Review 2.  Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review.

Authors:  Junxiong Pang; Min Xian Wang; Ian Yi Han Ang; Sharon Hui Xuan Tan; Ruth Frances Lewis; Jacinta I-Pei Chen; Ramona A Gutierrez; Sylvia Xiao Wei Gwee; Pearleen Ee Yong Chua; Qian Yang; Xian Yi Ng; Rowena Ks Yap; Hao Yi Tan; Yik Ying Teo; Chorh Chuan Tan; Alex R Cook; Jason Chin-Huat Yap; Li Yang Hsu
Journal:  J Clin Med       Date:  2020-02-26       Impact factor: 4.241

3.  SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.

Authors:  Hossein Poustchi; Maryam Darvishian; Zahra Mohammadi; Amaneh Shayanrad; Alireza Delavari; Ayad Bahadorimonfared; Saeid Eslami; Shaghayegh Haghjooy Javanmard; Ebrahim Shakiba; Mohammad Hossein Somi; Amir Emami; Nader Saki; Ahmad Hormati; Alireza Ansari-Moghaddam; Majid Saeedi; Fatemeh Ghasemi-Kebria; Iraj Mohebbi; Fariborz Mansour-Ghanaei; Manoochehr Karami; Hamid Sharifi; Farhad Pourfarzi; Nasrollah Veisi; Reza Ghadimi; Sareh Eghtesad; Ahmadreza Niavarani; Ali Ali Asgari; Anahita Sadeghi; Majid Sorouri; Amir Anushiravani; Mohammad Amani; Soudeh Kaveh; Akbar Feizesani; Payam Tabarsi; Hossein Keyvani; Melineh Markarian; Fatemeh Shafighian; Alireza Sima; Alireza Sadjadi; Amir Reza Radmard; Ali H Mokdad; Maryam Sharafkhah; Reza Malekzadeh
Journal:  Lancet Infect Dis       Date:  2020-12-15       Impact factor: 25.071

4.  Assessment of Seroprevalence of SARS-CoV-2 and Risk Factors Associated With COVID-19 Infection Among Outpatients in Virginia.

Authors:  Elizabeth T Rogawski McQuade; Kristin A Guertin; Lea Becker; Darwin Operario; Jean Gratz; Dave Guan; Fauzia Khan; Jennifer White; Timothy L McMurry; Bhruga Shah; Stephanie Garofalo; Matt Southerland; Kelly Bear; John Brush; Cynthia Allen; Amy Frayser; Rebecca Vokes; Rashmi Pershad; Lilian Peake; Christopher deFilippi; Kathleen Barackman; Gonzalo Bearman; Andrea Bidanset; Francis Farrell; David Trump; Eric R Houpt
Journal:  JAMA Netw Open       Date:  2021-02-01

5.  The role of asymptomatic and pre-symptomatic infection in SARS-CoV-2 transmission-a living systematic review.

Authors:  Xueting Qiu; Ali Ihsan Nergiz; Alberto Enrico Maraolo; Isaac I Bogoch; Nicola Low; Muge Cevik
Journal:  Clin Microbiol Infect       Date:  2021-01-21       Impact factor: 8.067

6.  Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19.

Authors:  Beatriz Böger; Mariana M Fachi; Raquel O Vilhena; Alexandre F Cobre; Fernanda S Tonin; Roberto Pontarolo
Journal:  Am J Infect Control       Date:  2020-07-10       Impact factor: 2.918

7.  SARS-CoV-2 (COVID-19) by the numbers.

Authors:  Yinon M Bar-On; Avi Flamholz; Rob Phillips; Ron Milo
Journal:  Elife       Date:  2020-04-02       Impact factor: 8.140

8.  Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19).

Authors:  Hiroshi Nishiura; Tetsuro Kobayashi; Takeshi Miyama; Ayako Suzuki; Sung-Mok Jung; Katsuma Hayashi; Ryo Kinoshita; Yichi Yang; Baoyin Yuan; Andrei R Akhmetzhanov; Natalie M Linton
Journal:  Int J Infect Dis       Date:  2020-03-14       Impact factor: 3.623

Review 9.  Asymptomatic SARS Coronavirus 2 infection: Invisible yet invincible.

Authors:  Lea A Nikolai; Christian G Meyer; Peter G Kremsner; Thirumalaisamy P Velavan
Journal:  Int J Infect Dis       Date:  2020-09-03       Impact factor: 3.623

Review 10.  The Epidemiological Characteristics of the COVID-19 Pandemic in Europe: Focus on Italy.

Authors:  Giovanni Gabutti; Erica d'Anchera; Francesco De Motoli; Marta Savio; Armando Stefanati
Journal:  Int J Environ Res Public Health       Date:  2021-03-13       Impact factor: 3.390

View more
  5 in total

1.  SARS-CoV-2 Seroprevalence in Healthcare Workers before the Vaccination in Poland: Evolution from the First to the Second Pandemic Outbreak.

Authors:  Izabela Korona-Głowniak; Michał Mielnik; Martyna Podgajna; Ewelina Grywalska; Marek Hus; Katarzyna Matuska; Beata Wojtysiak-Duma; Dariusz Duma; Andrzej Glowniak; Anna Malm
Journal:  Int J Environ Res Public Health       Date:  2022-02-17       Impact factor: 3.390

Review 2.  The Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic.

Authors:  Maria Karoliny da Silva Torres; Carlos David Araújo Bichara; Maria de Nazaré do Socorro de Almeida; Mariana Cayres Vallinoto; Maria Alice Freitas Queiroz; Izaura Maria Vieira Cayres Vallinoto; Eduardo José Melo Dos Santos; Carlos Alberto Marques de Carvalho; Antonio Carlos R Vallinoto
Journal:  Front Microbiol       Date:  2022-02-10       Impact factor: 5.640

3.  Seroprevalence of Anti-SARS-CoV-2 Antibodies in Benadir Region, Somalia.

Authors:  Mohamed Hussein Adam; Jamal Hasan Mohamoud; Abdiaziz S Mohamood; Ahmed A Mohamed; Bashiru Garba; Najib Isse Dirie
Journal:  Vaccines (Basel)       Date:  2022-01-30

4.  Antibodies to NCP, RBD and S2 SARS-CoV-2 in Vaccinated and Unvaccinated Healthcare Workers.

Authors:  Agata Błaszczuk; Aleksander Michalski; Maria Malm; Bartłomiej Drop; Małgorzata Polz-Dacewicz
Journal:  Vaccines (Basel)       Date:  2022-07-22

5.  Influence of the Demographic, Social, and Environmental Factors on the COVID-19 Pandemic-Analysis of the Local Variations Using Geographically Weighted Regression.

Authors:  Krzysztof Rząsa; Mateusz Ciski
Journal:  Int J Environ Res Public Health       Date:  2022-09-20       Impact factor: 4.614

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.